Biozentrum, University of Basel, Spitalstrasse 41, 4056, Basel, Switzerland.
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Nat Commun. 2023 Sep 13;14(1):5648. doi: 10.1038/s41467-023-41445-w.
The outer membrane insertase of Gram-negative bacteria, BAM, is a key target for urgently needed novel antibiotics. Functional reconstitutions of BAM have so far been limited to synthetic membranes and with low throughput capacity for inhibitor screening. Here, we describe a BAM functional assay in native membrane environment capable of high-throughput screening. This is achieved by employing outer membrane vesicles (OMVs) to present BAM directly in native membranes. Refolding of the model substrate OmpT by BAM was possible from the chaperones SurA and Skp, with the required SurA concentration three times higher than Skp. In the OMVs, the antibiotic darobactin had a tenfold higher potency than in synthetic membranes, highlighting the need for native conditions in antibiotics development. The assay is successfully miniaturized for 1536-well plates and upscaled using large scale fermentation, resulting in high-throughput capacities to screen large commercial compound libraries. Our OMV-based assay thus lays the basis for discovery, hit validation and lead expansion of antibiotics targeting BAM.
革兰氏阴性菌外膜插入酶 BAM 是急需新型抗生素的关键靶标。BAM 的功能重建迄今为止仅限于合成膜,并且抑制剂筛选的通量能力较低。在这里,我们描述了一种在天然膜环境中具有高通量筛选能力的 BAM 功能测定法。这是通过利用外膜囊泡 (OMV) 将 BAM 直接呈现在天然膜上来实现的。BAM 可以从伴侣蛋白 SurA 和 Skp 重新折叠模型底物 OmpT,SurA 的所需浓度比 Skp 高三倍。在 OMV 中,达罗巴坦的抗生素活性比在合成膜中高十倍,这凸显了在抗生素开发中需要天然条件。该测定法已成功微型化为 1536 孔板,并通过大规模发酵进行放大,从而具有筛选大型商业化合物库的高通量能力。因此,我们基于 OMV 的测定法为发现、命中验证和针对 BAM 的抗生素先导化合物的扩展奠定了基础。